Skip to content
Ensuring the sustained success of the biobased economy is of great importance to continued innovation, better patient outcomes, and the economic empowerment of many […]
How sound tax policy can strengthen biotech Read More »
In a new report, Preparing for the Next Pandemic in the Era of Antimicrobial Resistance, the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) outlined
PACCARB highlights looming threat of antimicrobial resistance Read More »
The Biden administration announced $5 billion in federal funding will be directed to Project NextGen, the anticipated successor to Operation Warp Speed. Project NextGen
Biden administration announces $5 billion successor to Operation Warp Speed Read More »
On April 11, the Biotechnology Innovation Organization (BIO) signed on to an amicus brief calling for the suspension of a Federal District Court ruling
BIO joins amicus brief against mifepristone ruling Read More »
More than 400 biotech leaders, including many Biotechnology Innovation Organization (BIO) members, have signed a statement condemning Friday’s ruling in a Texas federal court
BIO members, chair among 400 biotech leaders opposing Texas ruling Read More »
Orphan drugs are the fastest-growing segment of the pharmaceutical market, but the Inflation Reduction Act (IRA) clouds the future of new treatments for rare
Report sees booming orphan drug market threatened by price controls Read More »
Polls conducted by YouGov and Wakefield Research show the majority of Americans want the government to invest in better pandemic preparedness in the wake
Polls show Americans want better pandemic preparedness Read More »
On April 3, the Biden administration released a National Cancer Plan that seeks to coordinate government, research, and the biotech industry to cut cancer deaths
National Cancer Plan outlines government cooperation with biotech industry Read More »
The “benefits” pharmacy benefit managers (PBMs) once provided have been lost, as these organizations now mostly help themselves while driving up drug prices, said
Senate hearing looks at what went wrong with PBMs Read More »
The threat of expanding intellectual property waivers by the World Trade Organization (WTO) dampens investment in research, Biotechnology Innovation Organization’s (BIO) Chief Policy Officer
BIO opposes extension of WTO IP waiver in federal hearing Read More »
